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Summary Alteration of the tumour-suppressor gene p53 is the commonest genetic change encountered in human malignant tumours. A
study was undertaken to ascertain the prognostic value of p53 immunoexpression in nephroblastomas. A series of 93 consecutive cases was
analysed. Archival formalin-fixed, paraffin wax-embedded tissue sections were stained with monoclonal anti-p53 antibody (DO-7, Dako) using
a peroxidase-labelled streptavidin biotin kit. Five of seven tumours (71.4%) with unfavourable histology, but only 3 of 86 favourable histology
tumours, showed 'high' p53 immunoexpression (P< 0.001). p53 expression in unfavourable histology tumours was present in both anaplastic
and non-anaplastic components. Moreover, there was uniform staining of blastema, epithelium and stroma in unfavourable histology tumours.
No statistical difference in p53 expression was found between patients who had received and those who had not received preoperative
chemotherapy (P = 0.678). Similarly, no statistical difference was found in the groups of patients who were disease free, who had
residual/recurrent disease or who had died (P = 0.238). The mean survival period for patients with tumours that had 'low' and 'high'
expressions was 24.8 months and 12.6 months respectively (P = 0.0003). In conclusion, p53 immunoexpression in nephroblastomas was
found to be an important determinant of poor prognosis as it identifies those patients with a shorter survival period and also those with
unfavourable histology tumours. It may also be of practical value to the practising pathologist by identifying those tumours that require careful
assessment for the presence of anaplasia.
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Nephroblastoma or Wilms' tumour is one ofthe commonest solid
paediatric neoplasms with an incidence of approximately 1 in
10 000 children. There has been substantial improvement in the
prognosis of patients with nephroblastoma largely as a result
ofthe correct application ofchemo- and radiotherapy.
The role of gene protein expression in determining prognosis is
a relatively new investigative tool. The p53 gene, located on the
short arm ofchromosome 17 (17pl3), is the best known and most
intensively studied tumour-suppressor gene in human cancer.
Alterations in p53 are among the most common genetic changes
associated with human cancer, and this gene has been implicated
in the oncogenesis of a wide range of neoplasms (Levine et al,
1991; Batsakis and El-Naggar, 1995).
Wild-type p53 maintains genomic integrity by functioning as a
check point in the cell cycle at the G1/S transition (Kastan et al,
1992; Levine, 1992). Alterations of the p53 gene result in the
formation ofabnormal (mutant) p53 protein that has a longer half-
life than the wild-type protein (Batsakis and El-Naggar, 1995).
Mutant p53 protein may either lose its normal function or gain a
new function that inactivates wild-type protein (Deppert, 1994).
Although immunohistochemical detection of p53 protein is
neither aperfect nor acompletely accurate reflection ofunderlying
p53 mutations, there is good agreement between positive
immunohistochemical staining and mutations detected by DNA
sequencing (Batsakis and El-Naggar, 1995).
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Alterations in thep53 gene have been identified andimplicated in
the development of several human cancers, including colon, breast,
lung and brain (Levine et al, 1991; Batsakis and El-Naggar, 1995).
The p53 gene in nephroblastomas was studied by Bardeesy and
colleagues who found that p53 mutations were restricted to
anaplastic tumours only (Bardeesy et al, 1994). A few studies have
looked at the immunohistochemical expression of p53 protein in
nephroblastomas (Lemoine et al, 1992; Cheah et al, 1996) while
Lahoti etal (1996) looked atboth gene andprotein, butthese studies
had small patient numbers and some had limited follow-up data.
This study was conducted on 93 cases of nephroblastomas to
ascertain whether p53 protein immunoexpression is ofprognostic
value. p53 expression was correlated with the following parame-
ters: histological classification, disease stage and survival period.
In addition, this study represents the first analysis of this type on
an African cohort ofpatients.
MATERIALS AND METHODS
Ninety-three consecutive cases ofnephroblastomas were retrieved
from the files of the Department of Anatomical Pathology. The
tumours were liberally sampled with an average of20 blocks taken
and were classified into favourable and unfavourable histology
based on the presence or absence of anaplasia. Anaplasia was
diagnosed when the following three criteria were present
(Beckwith and Palmer, 1978): (1) an increase in nuclear diameter
at least three times that of adjacent nuclei of the same cell type;
(2) hyperchromatism of the enlarged nuclei; and (3) presence of
abnormal mitotic figures.
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Figure 1 Histological appearance of a nephroblastoma with unfavourable
histology: cells with bizarre, enlarged, hyperchromatic nuclei containing
abnormal mitoses (haematoxylin and eosin, x 100)
Figure 2 An example of 'low' p53 staining with fewer than 25% of cells
stained (anti-p53, x 100)
Table 1 p53 immunoexpression vs histological classification
p53 Histological classification
immunoexpression
Favourable (%) Unfavourable (%)
Low 83 (96.5) 2 (28.6)
High 3 (3.5) 5 (71.4)
A minimum of two and maximum of three paraffin wax-
embedded tissue blocks (those containing the least amount of
tumour necrosis) were selected from each case for immunohisto-
chemical staining. Tissue sections (2gm) were placed on poly-L-
lysine (Sigma diagnostics, St Louis, USA)-coated glass slides.
Tissue sections immersed in a 0.01 M sodium citrate (trihydrate)
solution were treated in a microwave (H2500 Microwave
Processor, Energy Beam Sciences, Agawam, MA, USA) at 85°C
for 10 min for antigen retrieval.
Endogenous peroxidase activity was blocked using an aqueous
solution of 3% hydrogen peroxide. Sections were stained with
monoclonal anti-p53 antibody (DO-7, Dako; dilution 1:100) using
theperoxidase-labelled streptavidin biotin kit(Dako). Thereaction
was visualized using diaminobenzidine (Liquid DAB, Dako) as a
chromogen. A case ofpoorly differentiated adenocarcinoma ofthe
colon, known to be immunoreactive forp53 (DO-7), was used as a
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Figure 3 p53 immunostaining in an anaplastic area. Note intense nuclear
labelling of all cells, including those that are large and pleomorphic (anti-p53,
x 25)
positive control. Negative controls, in which the primary antibody
was withheld, were also run simultaneously.
Only crisp nuclear staining was accepted as positive. The quan-
tity of nuclear staining was graded as follows: < 5%, negative;
6-25%, 1 +; 26-50%, 2 +; 51-75%, 3 +; and > 75%, 4 +. These
cases were then arbitrarily divided into 'no/low' (0-50%) and
'high' (51-100%). The number of tumour cells that were
immunopositive was expressed as a percentage ofthe total number
of tumour cells per high-power field (HPF). One hundred HPFs
were counted per slide and the final percentage was an average of
the 100 HPFs. The quantitation and grading was performed
manually using an Olympus BH2 microscope.
Clinical data were obtained from patient files kept in the
Department of Paediatric Surgery. p53 protein expression was
compared with clinicopathological stage, histological classifica-
tion and patient outcome using Fisher's exact test and the chi-
square test. The survival periods forgrades ofp53 expression were
compared using Student's t-test.
RESULTS
There were 49 female and 44 male patients with a F/M ratio of
1.1:1.0. The patient age at presentation ranged from 4 months to
14 years. The mean age at presentation was 3 years 7 months.
The first patient in this study was admitted on 13 January 1984
and the last patient on 4 May 1995, giving a time frame ofapprox-
imately 11 years. The last patient in this study has been followed
up for 12 months.
The overall follow-up period ranged from 1 month to 9 years 2
months, with a mean follow-up of 23.8 months. Fifty-six patients
were disease free at last follow-up, 16 had residual or recurrent
disease and 21 had died.
Sixteen patients had stage I disease, 24 had stage II, 23 had
stage III, 27 had stage IV and three had stage V disease. There
were 86 nephroblastomas with favourable histology and seven
with unfavourable histology. Nephroblastomas with unfavourable
histology (anaplastic) were identified by the presence ofenlarged,
hyperchromatic nuclei and multipolar mitotic figures (Figure 1).
Sixty-eight patients received preoperative chemotherapy
according to the SIOP (International Society of Paediatric
Oncology) protocol. The remaining 25 patients did not receive
preoperative chemotherapy.
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Figure 4 Tubular structures in an anaplastic variety of nephroblastoma
showing strong nuclear immunoreactivity for p53. Thus, in the anaplastic
nephroblastomas, high p53 protein expression was also present in non-
anaplastic ('favourable') areas (anti-p53, x 100)
Table 2 p53 immunoexpression vs clinicopathological stage
p53 Clinicopathological stage
immunoexpression
I (%) 11 (%) Il (%) IV (%) V (%)
Low 16 (100) 23 (95.8) 20 (87.0) 25 (92.6) 1 (33.3)
High 0 1 (4.2) 3 (13) 2 (7.4) 2 (66.7)
Table 3 p53 immunoexpression vs disease status
p53 Disease status
immunoexpression
Disease Alive with Died
free (%) disease (%) (%)
Low 53 (94.6) 13 (81.3) 19 (90.5)
High 3 (5.4) 3 (18.7) 2 (9.5)
Table 4 p53 immunoexpression vs survival
p53 Survival (months)
immunoexpression
< 6 (%) 6-12 (%) 12-18 (%) 18-24 (%) 2 24(%)
Low 13 (92.9) 21 (91.3) 14 (77.8) 8 (88.9) 29 (100)
High 1 (7.1) 2 (8.7) 4 (22.2) 1 (11.1) 0
In total, 85 tumours showed 'no/low' p53 expression (Figure 2)
and eight showed 'high' p53 expression. Normal kidney tissue,
whenever present, did not show immunoreactivity forp53.
When comparing p53 expression with histology (see Table 1),
five of the seven tumours (71.4%) with unfavourable histology
showed 'high' p53 expression, while only 3 of 86 (3.5%) tumours
with favourable histology showed similar expression. This differ-
ence was statistically significant (P < 0.001). Of the five tumours
with unfavourable histology that showed 'high' p53 expression,
four had diffuse anaplasia and the remaining one had focal
anaplasia. 'High' p53 expression in tumours with unfavourable
histology was present in both anaplastic (Figure 3) and non-
anaplastic cells. Non-anaplastic tubular and/or glomeruloid struc-
tures, present in three of seven anaplastic tumours, showed intense
nuclear staining (Figure 4). Furthermore, the 'high' expression in
the anaplastic tumours was present uniformly in blastema, stroma
and epithelium. Within the favourable histology group, three cases
showed 'high' p53 expression. Two of these patients have
recurrent disease and one patient died.
The results of p53 immunoexpression according to clinico-
pathological stage are shown in Table 2. All stage I tumours
showed 'low' p53 staining; in fact, all 16 cases in this stage were
either negative or showed less than 25% p53 immunostaining.
There were 39 cases that had a combination of low disease stage
(stage I and II) and favourable histology. All of these had 'low'
p53 expression. Conversely, there were 46 (44 cases were either
negative or showed 1 + p53 positivity) high-stage tumours also
with 'low' p53 expression. This also included cases with
favourable histology. This particular cohort of 46 cases had an
overall survival of23 months compared with 21.6 months survival
of all high-stage nephroblastomas. Similarly, seven high-stage
tumours with 'high' p53 levels were identified and this group had
an overall survival of only 12.7 months. Although a statistically
significant correlation was found between p53 immunoexpression
and disease stage (P = 0.004), this result may not be valid because
ofthe small number ofpatients with stage V tumours. Six patients
with stage II disease, favourable histology and 'low' p53 staining
died. Of these six patients, four died of treatment-related causes,
e.g. infection due to bone marrow suppression, one died of recur-
rent tumour and anotherpatient ofunrelated causes.
Tumours from 7 of the 68 patients that received preoperative
chemotherapy showed 'high' expression. In contrast, only one
tumour of the 25 that were not treated preoperatively showed
'high' expression. No statistical difference in p53 staining was
found between these two groups (P = 0.678).
Similarly, no statistical difference was found in p53 staining
in the groups of patients who were disease free, who had
residual/recurrent disease or who had died (P = 0.238) (Table 3).
Tumours from 3 of the 56 patients who were disease free showed
'high' expression. In addition, 3 ofthe 16 who had residual/recur-
rent disease and 2 ofthe 21 who died showed 'high' expression.
The results ofp53 immunoexpression versus survival are shown
in Table 4. The mean survival period forpatients with tumours that
showed 'low' expression was 24.8 months (range 1-110 months).
In contrast, the mean survival period for the 'high' expression
group was 12.6 months (range 2-19 months). This finding was
statistically significant (P = 0.0003, Student's t-test).
DISCUSSION
Several genetic aberrations have been implicated in the pathogen-
esis ofnephroblastomas. These include the following loci: lpl3,
1lplS and 16q (Maw et al, 1992). The most widely investigated is
the WTI gene, which is mapped to Ip13. The p53 gene has also
been suggested to play a role in the pathogenesis of nephro-
blastomas (Lemoine et al, 1992; Velasco et al, 1993).
This study looked at the prognostic significance ofthe immuno-
histochemical detection of p53 protein in nephroblastomas. It
should be emphasized that the immunohistochemical detection of
p53 protein is neither a perfect nor an accurate reflection ofunder-
lying p53 mutations, because mechanisms other than mutations
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may also result in p53 protein accumulation. Nevertheless, there is
good agreement between the frequency of positive immunohisto-
chemical staining and mutations detected by DNA sequencing
(Batsakis and El-Naggar, 1995). In contrast, Lahoti et al (1996)
found that most nephroblastomas with immunodetectable p53
protein did not havep53 mutations. They postulated that this may
be because ofthe presence ofmutations in regions not examined or
because the tumour overexpresses or retains wild-type p53. It has
been stated by Lahoti et al (1996) that the phenomenon oftumour
heterogeneity may cause variation in the results of immunohisto-
chemical and molecular analyses of tumour. It was therefore
recommended that multiple blocks be examined to ascertain
whether immunostaining varies from area to area. In this study, we
examined up to three blocks of non-necrotic tumour and did not
find a marked variation in staining patterns. The overall scoring of
different blocks from the same tumour remained the same.
Although no statistical difference in p53 expression was found
between the groups that received preoperative chemotherapy
and those that did not, we are aware that the administration
of chemotherapy may influence p53 protein expression (Moll
et al, 1995).
The finding of 'high' p53 expression in all cell types in tumours
with unfavourable histology is of practical value. Detection of
anaplasia (orunfavourable histology) is dependent on the thorough
examination and adequate sampling of the tumour specimen. It is
possible that, if the tumour is poorly sampled, anaplasia may not
be detected in some cases. If a tumour shows 'high' p53 expres-
sion and no anaplasia is found in the sections examined, additional
sections ofthe tumour should be examined carefully for anaplasia.
The NWTS also suggests generous sectioning of the tumour as
anaplasia may exist only focally (Beckwith, 1983); one generous
section for each centimetre of tumour diameter is the minimum
guideline. Proper and careful specimen-handling together with
tissue-sectioning is essential to avoid artefacts that may mimic
anaplasia. It may well be that tumours with 'high' p53 expression
may require more aggressive chemotherapy.
The survival period is shorter for 'high' p53-expressing
tumours. As mutant p53 may activate MDR] (multidrug resistant
gene) (Chin et al, 1992; Dittmer et al, 1993), the shorter survival
period in tumours with 'high' p53 expression may be related to
MDR] activation by p53. This is based on the assumption that the
'high' p53 expression detected immunohistochemically is due to
p53 mutations. Investigation ofMDRJ expression may reveal valu-
able prognostic information.
A subset ofpatients was identified who dieddespite having rela-
tively low disease stage and favourable histology. All these cases
showed 'low' p53 staining. mdm2 overexpression may overcome
p53-regulated growth control in the absence of p53 mutations
(Oliner et al, 1992; Reifenberger et al, 1993). Therefore, in
tumours with intactp53 and wild-type protein, mdm2 overexpres-
sion may be responsible for the inactivation ofp53 in an autoregu-
latory fashion (Wu et al, 1993).
It is also possible that there are interactions between p53 and
other cellular proteins. Evidence is accruing that the cellular
environment plays a crucial role in p53 stability and, ultimately,
immunodetection. Therefore, p53 protein expression may be a
reflection of not only p53 gene mutations but also other cellular
and/or genetic events. It has been shown that p53 interacts with
various viral gene products, such as human papilloma virus E6,
simian virus 40 T-antigen and adenovirus EIB (Lane and
Crawford, 1979; Mietz et al, 1992; Yew and Berk, 1992). Cellular
proteins, heat shock protein 70, mdm2 and transcriptional factor
WT1 are also associated with p53 (Maheswaran et al, 1993; Wu et
al, 1993, Lane, 1994; Sturzbecher and Deppert, 1994).
The poor prognosis of anaplastic tumours is thought to be
because of the resistance of this variant to chemotherapy rather
than to any inherent aggressive behaviour. Anaplasia confined to
the kidney, i.e. stage I disease, has been found to have no effect on
prognosis (Zuppan et al, 1988; Murphy et al, 1994).
Whatever the mechanism, it is clear from this study that p53
immunoexpression is of importance to both those diagnosing and
treating nephroblastomas.
This study is in agreement with previous studies ofp53 analysis
in nephroblastomas, in which anaplasia was associated with signif-
icantly high levels ofp53 expression (Cheah et al, 1996; Lahoti et
al, 1996). However, there are additional features that emanate from
the current study. p53 immunoexpression is low or negative in the
majority ofnephroblastomas (85 of 93). 'No/low' p53 expression
occurs in all stages, i.e. there is no correlation with disease stage.
'High' expression is seen in nephroblastomas with unfavourable
histology, with five ofeight tumours with 'high' expression being
anaplastic. Although, only seven anaplastic tumours were investi-
gated here, the overall incidence of anaplasia in this study (7.5%)
is similar to those reported in other studies.
In conclusion, 'high' p53 protein expression in nephroblast-
omas is a predictor ofpoor prognosis. It identifies, firstly, a histo-
logical type associated with unfavourable outcome and, secondly,
a group ofpatients with a shorter survival period. Both these indi-
cators are independent of disease stage. Furthermore, tumours
with 'high' p53 protein expression should be carefully examined
for the presence ofanaplasia.
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